Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-2
- Development stage
- Preclinical
- Lead developer
- Porosome Therapeutics
- Modality
- Peptides
01
Overview
AB-2 is a peptide-based therapeutic candidate under development by Porosome Therapeutics for the treatment of melanoma. It belongs to the company's "Porosome Peptide Therapy" platform, which targets the porosome—a cup-shaped lipoprotein structure at the plasma membrane that serves as the universal secretory portal in cells. By modulating the secretory pathways through which cancer cells communicate or release growth factors, AB-2 aims to provide a novel approach to treating malignant melanoma. The drug is currently in the early-to-mid stages of development, following the company's lead melanoma candidate, AB-1.
Beyond the preview
Go deeper on AB-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-2.